

Publication

Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone : results of three multicentre trials

JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)

ID 1195342

Author(s) Bitzer, Johannes; Paoletti, Anna M

Author(s) at UniBasel [Bitzer, Johannes](#) ;

Year 2009

Title Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone : results of three multicentre trials

Journal Clinical drug investigation

Volume 29

Number 2

Pages / Article-Number 73-8

The ethinylestradiol 20 mug/drospirenone 3 mg combined oral contraceptive (COC), administered in cycles of 21 days continuous use followed by a 7-day hormone-free interval (21/7) [Yasminelle((R))], has been proven to be an effective and well tolerated contraceptive with an acceptable bleeding pattern and good safety profile. In addition, the ethinylestradiol 20 mug/drospirenone 3 mg 21/7 COC prevents water-retention-related weight gain, and improves physical and emotional well-being, consistent with other drospirenone-containing COCs. In clinical studies, >85% of those who received the ethinylestradiol 20 mug/drospirenone 3 mg 21/7 COC were satisfied or very satisfied with this contraceptive. The positive attributes of the ethinylestradiol 20 mug/drospirenone 3 mg 21/7 COC beyond contraceptive protection may have important implications for improving treatment compliance and reducing treatment discontinuation. Physical well-being stayed the same or improved during use of this COC in 56% and 34% of women, respectively. Emotional well-being stayed the same or improved in 71% and 20% of women, respectively.

Publisher Wolters Kluwer Adis

ISSN/ISBN 1173-2563

edoc-URL <http://edoc.unibas.ch/dok/A6005525>

Full Text on edoc No;

Digital Object Identifier DOI 10.2165/0044011-200929020-00001

PubMed ID <http://www.ncbi.nlm.nih.gov/pubmed/19133702>

ISI-Number WOS:000262820000001

Document type (ISI) Journal Article, Review